Close

Drug Research

Sanofi, Fraunhofer create new natural product center of excellence

French pharmaceutical firm Sanofi and Germany-based Fraunhofer-Gesellschaft have formed a natural product center of excellence to speed up the discovery and development of new therapies to treat infectious diseases. As part of the deal, Sanofi...

Galena Biopharma, Dr. Reddy’s partner for NeuVax in India

Galena Biopharma and Dr. Reddy's Laboratories have entered into a strategic development and commercialization partnership on NeuVax (nelipepimut-S) in India. NeuVax (nelipepimut-S) is the immunodominant nonapeptide derived from the extracellular domain of the HER2 protein...

Cellceutix provides updates on clinical trials and developments of Its anti-cancer, anti-psoriasis, and antibiotic compounds

Cellceutix, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, today provides shareholders with an update on the current status of the Company's compounds in development. Kevetrin, anti-cancer compound in...

Mission Pharmacal introduces new oral spray for dry mouth

US-based pharmaceutical firm Mission Pharmacal has launched a new safe and effective protective oral spray called Aquoral that moistens and lubricates the mouth for up to four hours. Dry mouth (xerostomia), which affects about 25...

Alzheon to advance ALZ-801 into Phase II trial in patients with Alzheimer’s disease

Alzheon announced the launch of the company, the securing of initial private financing, and the signing of an exclusive license agreement to a novel clinical drug candidate for Alzheimer’s disease, a family of analogs, and a drug development platform...

InnoCore, Allergan to develop new drug delivery products for ophthalmic diseases

Netherland-based injectable drug delivery products producer InnoCore Pharmaceuticals has signed an exclusive license and collaboration agreement with Allergan (AGN), to develop new medicines for ophthalmic diseases. The deal will see the companies expand their existing...

Adimab, Celgene form drug discovery partnership

Adimab signed a multi-target discovery agreement with Celgene Corporation, pursuant to which, Adimab will use its proprietary discovery and optimization platform to generate fully human antibodies against multiple targets. Under the terms of the agreement,...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read